Skip to main content



Research Update: Using T cells to Tackle Drug Resistance in EGFR+ Lung Cancer

*March 2024* Approximately 10%-15% of patients with non-small cell lung cancer have tumors with mutations in the EGFR (epidermal growth factor receptor) gene. EGFR mutations are known to drive cancer growth. Many patients living with EGFR-positive lung cancer benefit from targeted therapies called tyrosine kinase inhibitors (TKIs). TKIs, such as osimertinib, can help…

Drs. Susumu Kobayashi and Alexandre Reuben Announced as Recipients of EGFR Resisters/LUNGevity Research Award

*November 2023* WASHINGTON, DC (November 1, 2023) – LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, is thrilled to announce the recipients of the EGFR Resisters/LUNGevity Research Award for EGFR-Positive Lung Cancer. EGFR Resisters, a vibrant patient-led community advocating for improved treatment options for patients with EGFR-positive lung cancer,…
December 24, 2023
EGFR Resisters logo
EGFR Resisters and LCRF Research Partnership: First Study Grant Awarded! FundingResearchTreatments

EGFR Resisters and LCRF Research Partnership: First Study Grant Awarded!

*December 2021* Our first $150,000 LCRF grant awarded to Yang Tian, PhD from the Icahn School of Medicine at Mount Sinai. Her project is titled, “Targeting lung lineage plasticity to suppress Osimertinib-induced drug-tolerant persisters. Please view the announcement of this lung cancer study video here.
December 7, 2021